NeoGenomics Historical Balance Sheet

NEO Stock

USD 9.99 0.17 1.73%

Trend analysis of NeoGenomics balance sheet accounts such as Total Stockholder Equity of 947.5 M provides information on NeoGenomics' total assets, liabilities, and equity, which is the actual value of NeoGenomics to its prevalent stockholders. By breaking down trends over time using NeoGenomics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining NeoGenomics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NeoGenomics is a good buy for the upcoming year.

NeoGenomics Inventory

28.09 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

About NeoGenomics Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of NeoGenomics at a specified time, usually calculated after every quarter, six months, or one year. NeoGenomics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of NeoGenomics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which NeoGenomics currently owns. An asset can also be divided into two categories, current and non-current.

NeoGenomics Balance Sheet Chart

At this time, NeoGenomics' Cash And Short Term Investments are very stable compared to the past year. As of the 2nd of March 2025, Liabilities And Stockholders Equity is likely to grow to about 1.7 B, though Retained Earnings are likely to grow to (309.5 M).

Total Assets Total Current Liabilities Accounts Payable Cash And Short Term Investments

Add Fundamental

Total Assets

Total assets refers to the total amount of NeoGenomics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NeoGenomics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on NeoGenomics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of NeoGenomics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents NeoGenomics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of NeoGenomics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of NeoGenomics balance sheet. This account contains NeoGenomics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by NeoGenomics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most accounts from NeoGenomics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into NeoGenomics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.At this time, NeoGenomics' Cash And Short Term Investments are very stable compared to the past year. As of the 2nd of March 2025, Liabilities And Stockholders Equity is likely to grow to about 1.7 B, though Retained Earnings are likely to grow to (309.5 M).

	2022	2023	2024	2025 (projected)
Cash	263.2M	342.5M	367.0M	385.4M
Accounts Payable	20.5M	20.3M	21.6M	12.3M

Cash Accounts Payable

NeoGenomics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Non Current Assets Total	Other Current Assets	Other Stockholder Equity	Property Plant And Equipment Gross	Property Plant Equipment	Short Long Term Debt Total	Current Deferred Revenue	Non Currrent Assets Other	Other Assets	Net Receivables
Total Assets		0.68	0.73	0.99	0.88	-0.71	0.31	0.96	0.98	-0.19	0.78	0.99	0.99	0.99	-0.19	0.99	1.0	0.96	0.97	0.98	0.93	0.98	0.77	-0.02	0.26	0.94
Other Current Liab	0.68		0.99	0.63	0.6	-0.89	0.02	0.76	0.62	-0.12	0.33	0.71	0.72	0.67	-0.11	0.63	0.68	0.79	0.72	0.77	0.56	0.73	0.38	0.16	0.07	0.75
Total Current Liabilities	0.73	0.99		0.69	0.61	-0.88	0.17	0.79	0.66	-0.18	0.43	0.74	0.76	0.72	-0.17	0.68	0.72	0.81	0.76	0.8	0.62	0.76	0.44	0.16	0.1	0.82
Total Stockholder Equity	0.99	0.63	0.69		0.83	-0.65	0.37	0.95	0.98	-0.2	0.81	0.96	0.97	0.99	-0.2	1.0	0.99	0.95	0.95	0.96	0.94	0.96	0.8	0.02	0.33	0.94
Net Debt	0.88	0.6	0.61	0.83		-0.71	0.08	0.75	0.81	-0.15	0.62	0.93	0.92	0.81	-0.15	0.82	0.9	0.82	0.82	0.89	0.79	0.92	0.57	-0.33	-0.08	0.75
Retained Earnings	-0.71	-0.89	-0.88	-0.65	-0.71		-0.05	-0.75	-0.63	0.15	-0.43	-0.76	-0.77	-0.67	0.14	-0.64	-0.72	-0.76	-0.75	-0.81	-0.48	-0.78	-0.37	0.07	0.07	-0.76
Accounts Payable	0.31	0.02	0.17	0.37	0.08	-0.05		0.27	0.24	-0.32	0.62	0.2	0.24	0.31	-0.32	0.34	0.32	0.2	0.3	0.19	0.32	0.21	0.27	0.09	0.2	0.49
Cash	0.96	0.76	0.79	0.95	0.75	-0.75	0.27		0.97	-0.16	0.71	0.94	0.95	0.98	-0.15	0.96	0.94	0.98	0.98	0.96	0.86	0.94	0.74	0.13	0.33	0.92
Cash And Short Term Investments	0.98	0.62	0.66	0.98	0.81	-0.63	0.24	0.97		-0.15	0.74	0.96	0.96	0.99	-0.15	0.98	0.96	0.96	0.97	0.96	0.92	0.95	0.78	0.01	0.34	0.88
Common Stock Total Equity	-0.19	-0.12	-0.18	-0.2	-0.15	0.15	-0.32	-0.16	-0.15		-0.51	-0.16	-0.18	-0.19	1.0	-0.2	-0.19	-0.19	-0.17	-0.16	-0.22	-0.17	0.23	-0.04	-0.08	-0.29
Common Stock Shares Outstanding	0.78	0.33	0.43	0.81	0.62	-0.43	0.62	0.71	0.74	-0.51		0.71	0.73	0.77	-0.5	0.81	0.78	0.68	0.71	0.7	0.75	0.71	0.59	0.02	0.37	0.81
Non Current Liabilities Total	0.99	0.71	0.74	0.96	0.93	-0.76	0.2	0.94	0.96	-0.16	0.71		1.0	0.97	-0.16	0.96	0.99	0.96	0.96	0.99	0.9	1.0	0.71	-0.09	0.15	0.9
Total Liab	0.99	0.72	0.76	0.97	0.92	-0.77	0.24	0.95	0.96	-0.18	0.73	1.0		0.97	-0.17	0.96	0.99	0.97	0.96	0.99	0.9	1.0	0.72	-0.07	0.16	0.92
Total Current Assets	0.99	0.67	0.72	0.99	0.81	-0.67	0.31	0.98	0.99	-0.19	0.77	0.97	0.97		-0.18	0.99	0.97	0.97	0.98	0.97	0.92	0.96	0.78	0.04	0.35	0.93
Common Stock	-0.19	-0.11	-0.17	-0.2	-0.15	0.14	-0.32	-0.15	-0.15	1.0	-0.5	-0.16	-0.17	-0.18		-0.2	-0.19	-0.18	-0.17	-0.16	-0.21	-0.16	0.23	-0.04	-0.08	-0.29
Property Plant And Equipment Net	0.99	0.63	0.68	1.0	0.82	-0.64	0.34	0.96	0.98	-0.2	0.81	0.96	0.96	0.99	-0.2		0.98	0.94	0.95	0.95	0.93	0.95	0.81	0.03	0.39	0.93
Non Current Assets Total	1.0	0.68	0.72	0.99	0.9	-0.72	0.32	0.94	0.96	-0.19	0.78	0.99	0.99	0.97	-0.19	0.98		0.95	0.95	0.98	0.92	0.99	0.76	-0.06	0.21	0.94
Other Current Assets	0.96	0.79	0.81	0.95	0.82	-0.76	0.2	0.98	0.96	-0.19	0.68	0.96	0.97	0.97	-0.18	0.94	0.95		0.98	0.98	0.89	0.97	0.66	0.08	0.25	0.9
Other Stockholder Equity	0.97	0.72	0.76	0.95	0.82	-0.75	0.3	0.98	0.97	-0.17	0.71	0.96	0.96	0.98	-0.17	0.95	0.95	0.98		0.97	0.85	0.96	0.68	-0.01	0.27	0.91
Property Plant And Equipment Gross	0.98	0.77	0.8	0.96	0.89	-0.81	0.19	0.96	0.96	-0.16	0.7	0.99	0.99	0.97	-0.16	0.95	0.98	0.98	0.97		0.87	0.99	0.71	-0.05	0.17	0.91
Property Plant Equipment	0.93	0.56	0.62	0.94	0.79	-0.48	0.32	0.86	0.92	-0.22	0.75	0.9	0.9	0.92	-0.21	0.93	0.92	0.89	0.85	0.87		0.88	0.72	0.14	0.28	0.84
Short Long Term Debt Total	0.98	0.73	0.76	0.96	0.92	-0.78	0.21	0.94	0.95	-0.17	0.71	1.0	1.0	0.96	-0.16	0.95	0.99	0.97	0.96	0.99	0.88		0.7	-0.09	0.15	0.9
Current Deferred Revenue	0.77	0.38	0.44	0.8	0.57	-0.37	0.27	0.74	0.78	0.23	0.59	0.71	0.72	0.78	0.23	0.81	0.76	0.66	0.68	0.71	0.72	0.7		0.0	0.41	0.71
Non Currrent Assets Other	-0.02	0.16	0.16	0.02	-0.33	0.07	0.09	0.13	0.01	-0.04	0.02	-0.09	-0.07	0.04	-0.04	0.03	-0.06	0.08	-0.01	-0.05	0.14	-0.09	0.0		0.52	0.11
Other Assets	0.26	0.07	0.1	0.33	-0.08	0.07	0.2	0.33	0.34	-0.08	0.37	0.15	0.16	0.35	-0.08	0.39	0.21	0.25	0.27	0.17	0.28	0.15	0.41	0.52		0.33
Net Receivables	0.94	0.75	0.82	0.94	0.75	-0.76	0.49	0.92	0.88	-0.29	0.81	0.9	0.92	0.93	-0.29	0.93	0.94	0.9	0.91	0.91	0.84	0.9	0.71	0.11	0.33

Click cells to compare fundamentals

NeoGenomics Account Relationship Matchups

NeoGenomics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	988.3M	1.9B	1.7B	1.7B	1.6B	1.7B
Other Current Liab	39.2M	56.1M	55.2M	68.2M	269.1M	282.5M
Total Current Liabilities	73.2M	87.2M	89.9M	96.3M	301.2M	316.3M
Total Stockholder Equity	694.3M	1.1B	998.0M	941.5M	902.3M	947.5M
Net Debt	(10.5M)	296.0M	347.7M	269.2M	238.3M	250.2M
Retained Earnings	(7.2M)	(14.8M)	(159.1M)	(247.1M)	(325.8M)	(309.5M)
Accounts Payable	25.0M	17.9M	20.5M	20.3M	21.6M	12.3M
Cash	228.7M	316.8M	263.2M	342.5M	367.0M	385.4M
Cash And Short Term Investments	296.3M	515.4M	438.0M	415.2M	386.8M	406.2M
Common Stock Total Equity	105K	112K	124K	127K	114.3K	102.7K
Common Stock Shares Outstanding	111.8M	120.0M	124.2M	125.5M	126.7M	63.6M
Liabilities And Stockholders Equity	988.3M	1.9B	1.7B	1.7B	1.6B	1.7B
Non Current Liabilities Total	220.9M	674.3M	652.1M	643.4M	623.5M	654.6M
Total Liab	294.0M	761.5M	742.0M	739.7M	735.7M	772.5M
Total Current Assets	448.7M	681.5M	605.3M	596.8M	596.0M	625.8M
Common Stock	105K	112K	124K	127K	128K	102.7K
Property Plant And Equipment Net	151.9M	211.7M	198.6M	183.8M	173.7M	182.4M
Non Current Assets Total	539.6M	1.2B	1.1B	1.1B	1.0B	1.1B
Other Current Assets	16.1M	30.6M	23.3M	26.2M	31.9M	33.5M
Other Stockholder Equity	701.4M	1.1B	1.2B	1.2B	1.2B	1.3B
Property Plant And Equipment Gross	131.7M	321.6M	330.5M	342.0M	363.7M	381.9M
Accumulated Other Comprehensive Income	10K	(638K)	(3.9M)	(1.7M)	(206K)	(216.3K)
Property Plant Equipment	64.2M	85.9M	211.7M	102.5M	117.9M	123.8M
Short Long Term Debt Total	218.2M	612.8M	610.9M	611.7M	605.3M	635.6M
Current Deferred Revenue	4.0M	5.2M	7.6M	2.1M	409K	429.5K
Non Currrent Assets Other	21.0M	7.2M	(29.7M)	4.7M	5.9M	6.2M
Other Assets	2.8M	54.4M	7.2M	5.1M	5.9M	3.8M
Net Receivables	106.8M	112.1M	119.7M	131.3M	150.5M	158.1M
Inventory	29.5M	23.4M	24.3M	24.2M	26.7M	28.1M
Short Term Debt	7.8M	8.0M	6.7M	5.6M	6.8M	7.7M
Long Term Debt	168.1M	532.5M	535.3M	538.2M	340.3M	357.4M
Other Liab	17.1M	10.4M	69.5M	47.8M	55.0M	57.7M
Net Tangible Assets	182.2M	362.6M	138.8M	67.0M	77.0M	70.4M
Good Will	198.6M	211.1M	527.1M	522.8M	601.2M	631.2M
Retained Earnings Total Equity	(11.4M)	(7.2M)	(14.8M)	(159.1M)	(143.2M)	(136.0M)
Long Term Debt Total	115.9M	168.1M	532.5M	535.3M	615.6M	646.4M
Capital Surpluse	520.3M	701.4M	1.1B	1.2B	1.3B	1.4B
Capital Lease Obligations	50.1M	80.3M	75.6M	73.5M	64.2M	67.4M
Deferred Long Term Liab	15.6M	5.4M	55.5M	34.8M	40.0M	42.0M

Pair Trading with NeoGenomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.

Moving together with NeoGenomics Stock

0.83

ILMN

Illumina Sell-off Trend

Pair Corr

Moving against NeoGenomics Stock

0.83	FNMA	Federal National Mortgage	Pair Corr
0.78	MPW	Medical Properties Trust Trending	Pair Corr
0.42	PFE	Pfizer Inc	Pair Corr

The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.

The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:

How To Invest In NeoGenomics

Details

Is NeoGenomics Stock a good investment?

Details

What is NeoGenomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.306

Earnings Share

(0.62)

Revenue Per Share

5.215

Quarterly Revenue Growth

0.106

Return On Assets

(0.03)

The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NeoGenomics Historical Balance Sheet

NeoGenomics Inventory

28.09 Million

About NeoGenomics Balance Sheet Analysis

NeoGenomics Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Cash And Short Term Investments

NeoGenomics balance sheet Correlations

NeoGenomics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NeoGenomics balance sheet Accounts

Pair Trading with NeoGenomics

Moving together with NeoGenomics Stock

Moving against NeoGenomics Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Total Stockholder Equity
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Short Long Term Debt Total	+ 1.0	Non Current Liabilities Total
Short Long Term Debt Total	+ 1.0	Total Liab

Retained Earnings	- 0.89	Other Current Liab
Retained Earnings	- 0.88	Total Current Liabilities
Property Plant And Equipment Gross	- 0.81	Retained Earnings
Short Long Term Debt Total	- 0.78	Retained Earnings
Total Liab	- 0.77	Retained Earnings
Net Receivables	- 0.76	Retained Earnings